Low dose of liraglutide combined with metformin leads to a significant weight loss in Chinese Han women with polycystic ovary syndrome: a retrospective study

References

• Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):1–7. doi: 10.1038/nrendo.2018.24.
   PubMed Web of Science ®Google Scholar
• Li R, Zhang Q, Yang D, et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study. Hum Reprod. 2013;28(9):2562–2569. doi: 10.1093/humrep/det262.
   PubMed Web of Science ®Google Scholar
• Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–2855. doi: 10.1093/humrep/dew218.
   PubMed Web of Science ®Google Scholar
• Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome. Lancet Diabet Endocrinol. 2022;10(9):668–680. doi: 10.1016/S2213-8587(22)00163-2.
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: etiology, treatment, and genetics. Metabolism. 2019;92:108–120. doi: 10.1016/j.metabol.2018.11.002.
   PubMed Web of Science ®Google Scholar
• Palomba S, Piltonen TT, Giudice LC. Endometrial function in women with polycystic ovary syndrome: a comprehensive review. Hum Reprod Update. 2021;27(3):584–618. doi: 10.1093/humupd/dmaa051.
   PubMed Web of Science ®Google Scholar
• Moran L, Gibson-Helm M, Teede H, et al. Polycystic ovary syndrome: a biopsychosocial understanding in young women to improve knowledge and treatment options. J Psychosom Obstet Gynaecol. 2010;31(1):24–31. doi: 10.3109/01674820903477593.
   PubMed Web of Science ®Google Scholar
• Jiskoot G, van der Kooi AL, Busschbach J, et al. Cognitive behavioural therapy for depression in women with PCOS: systematic review and meta-analysis. Reproduct Biomed Online. 2022;45(3):599–607. doi: 10.1016/j.rbmo.2022.05.001.
   PubMed Web of Science ®Google Scholar
• Boucher J, Kleinridders A, Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014;6(1):231.
   PubMed Web of Science ®Google Scholar
• Moghetti P, Tosi F. Insulin resistance and PCOS: chicken or egg? J Endocrinol Invest. 2021;44(2):233–244. doi: 10.1007/s40618-020-01351-0.
   PubMed Web of Science ®Google Scholar
• Gu Y, Zhou G, Zhou F, et al. Life modifications and PCOS: old story but new tales. Front Endocrinol. 2022;13:808898. doi: 10.3389/fendo.2022.808898.
   PubMed Web of Science ®Google Scholar
• Moran LJ, Hutchison SK, Norman RJ, et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011;(7):CD007506.
   Web of Science ®Google Scholar
• Nuzzo A, Czernichow S, Hertig A, et al. Prevention and treatment of nutritional complications after bariatric surgery. Lancet Gastroenterol Hepatol. 2021;6(3):238–251. doi: 10.1016/S2468-1253(20)30331-9.
   PubMed Web of Science ®Google Scholar
• Tso LO, Costello MF, Albuquerque LET, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2020;12(12):CD006105. doi: 10.1002/14651858.CD006105.pub4.
   PubMedGoogle Scholar
• Garzia E, Galiano V, Marfia G, et al. Hyperandrogenism and menstrual imbalance are the best predictors of metformin response in PCOS patients. Reprod Biol Endocrinol. 2022;20(1):6. doi: 10.1186/s12958-021-00876-0.
   PubMed Web of Science ®Google Scholar
• Harborne LR, Sattar N, Norman JE, et al. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab. 2005;90(8):4593–4598. doi: 10.1210/jc.2004-2283.
   PubMed Web of Science ®Google Scholar
• Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155. doi: 10.3389/fendo.2019.00155.
   PubMed Web of Science ®Google Scholar
• van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014;38(6):784–793. doi: 10.1038/ijo.2013.162.
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. doi: 10.1136/bmj.d7771.
   PubMed Web of Science ®Google Scholar
• Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab. 2009;11(Suppl 3):26–34. doi: 10.1111/j.1463-1326.2009.01075.x.
   PubMed Web of Science ®Google Scholar
• Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719–1730. doi: 10.1056/NEJMoa2028198.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–699. doi: 10.1001/jama.2015.9676.
   PubMed Web of Science ®Google Scholar
• He L, Wang J, Ping F, et al. Association of Glucagon-Like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513–519. doi: 10.1001/jamainternmed.2022.0338.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Ni R, Hong Y, et al. Defining hyperandrogenaemia according to the free androgen index in chinese women: a cross-sectional study. Clin Endocrinol (Oxf). 2012;77(3):446–452. doi: 10.1111/j.1365-2265.2012.04395.x.
   PubMed Web of Science ®Google Scholar
• Xing XY, Yang WY. The diagnostic significance of homeostasis model assessment of insulin resistance in metabolic syndrome among subjects with different glucose tolerance. Chinese J Diabet. 2004;12(3):182–186.
   Google Scholar
• Jensterle Sever M, Kocjan T, Pfeifer M, et al. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014;170(3):451–459. doi: 10.1530/EJE-13-0797.
   PubMed Web of Science ®Google Scholar
• Rasmussen CB, Lindenberg S. The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study. Front Endocrinol (Lausanne). 2014;5:140. doi: 10.3389/fendo.2014.00140.
   PubMed Web of Science ®Google Scholar
• Kappe C, Patrone C, Holst JJ, et al. Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. J Gastroenterol. 2013;48(3):322–332. doi: 10.1007/s00535-012-0637-5.
   PubMed Web of Science ®Google Scholar
• Maida A, Lamont BJ, Cao X, et al. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia. 2011;54(2):339–349. doi: 10.1007/s00125-010-1937-z.
   PubMed Web of Science ®Google Scholar
• Cuthbertson J, Patterson S, O'Harte FP, et al. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism. 2011;60(1):52–56. doi: 10.1016/j.metabol.2010.01.001.
   PubMed Web of Science ®Google Scholar
• Green BD, Irwin N, Duffy NA, et al. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol. 2006;547(1–3):192–199. doi: 10.1016/j.ejphar.2006.07.043.
   PubMed Web of Science ®Google Scholar
• Rocha MP, Marcondes JA, Barcellos CR, et al. Dyslipidemia in women with polycystic ovary syndrome: incidence, pattern and predictors. Gynecol Endocrinol. 2011;27(10):814–819. doi: 10.3109/09513590.2010.508852.
   PubMed Web of Science ®Google Scholar
• Wing RR, Tate DF, Garcia KR, et al. Improvements in cardiovascular risk factors in young adults in a randomized trial of approaches to weight gain prevention. Obesity (Silver Spring). 2017;25(10):1660–1666. doi: 10.1002/oby.21917.
   PubMed Web of Science ®Google Scholar